Category: Uncategorized


  • In the traditional world of clinical trials, a CRO manages the study while a CDMO handles the manufacturing. This model works — until you apply it to Cell & Gene Therapy (CGT). And then, it breaks. Unlike conventional pharma, CGT trials don’t just test a product — they orchestrate a complex, patient-specific supply chain. Every…

  • CGT manufacturing is breaking out of the cleanroom and moving closer to the patient. What does this mean for healthcare professionals, CDMOs—and biotech strategy itself? From hybrid networks to digital-first production and bedside co-manufacturing, the rules are being rewritten. We’re standing at the edge of a manufacturing revolution in Cell and Gene Therapy (CGT). An…